Scotiabank analyst George Farmer lowered the firm’s price target on Syndax (SNDX) to $18 from $23 and keeps a Sector Perform rating on the shares. The firm lowered its price target on the stock due to what it views as an increased risk of securing FDA approval of revumenib for the treatment of relapsed-refractory acute myeloid leukemia harboring NPM-1 mutation, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Leerink views Syndax data as potentially positive for Kura Oncology’s ziftomenib
- Elliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz
- Syndax’s revumenib meets primary results in AML trial
- Syndax price target raised to $47 from $45 at H.C. Wainwright
- Syndax Pharmaceuticals: Key Pipeline Developments and Financial Update